40 citations
,
August 2022 in “Frontiers in immunology”
This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.
This study found that a quinazoline derivative, SH-340, increased skin barrier-associated factors and inhibited TSLP expression and STAT6 phosphorylation in human primary keratinocytes, suggesting potential benefits for alleviating inflammation and improving skin barrier function in atopic dermatitis.
June 2024 in “Journal of Allergy and Clinical Immunology”
In this study, thymic stromal lymphopoietin (TSLP) induced IL-4/IL-13 from T cells, prompting sebum secretion and adipose loss, suggesting IL-4/IL-13 may affect skin barrier function in atopic dermatitis.
In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.